Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) released its quarterly earnings data on Monday. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61), RTT News reports. During the same period in the prior year, the business earned ($1.18) EPS. Kestra Medical Technologies updated its FY 2025 guidance to EPS.
Kestra Medical Technologies Stock Performance
KMTS traded down $0.08 during midday trading on Friday, reaching $24.50. 135,353 shares of the company's stock were exchanged, compared to its average volume of 267,115. Kestra Medical Technologies has a 1-year low of $20.00 and a 1-year high of $26.15.
Analyst Ratings Changes
KMTS has been the topic of several research analyst reports. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $28.00 price target on the stock. Piper Sandler initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "overweight" rating and a $27.00 target price for the company. Wolfe Research initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "overweight" rating and a $28.00 price target for the company. Finally, The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a report on Wednesday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.
View Our Latest Report on KMTS
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
See Also
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
